Factors That Influence The Response To Daratumumab

OFFER DESCRIPTION Multiple Myeloma (MM) is a hematologic neoplasm characterized by the presence of tumoral plasma cells which produce a monoclonal immunoglobulin, whose accumulation induce organ damages and clinical symptoms as hypercalcemia, renal impairment, anaemia and bone lesions.
The evolution of techniques for the evaluation of mínimal residual disease (MRD), as next generation flow (NGF), permit a better quantification of the disease, and to recognize those patients able to achieve Complete Response.
Daratumumab, a monoclonal antibody binding the CD38 receptor onmonoclonal plasma cells, inducing their death by apoptosis, could be a good drug as a consolidation therapy; however, there is the need to clarify the mechanisms who might influence treatment response, such as the role of immunity or of the microenvironment in which tumour cells survive and proliferate More Information Additional Information Eligibility criteriaEligible destination country/ies for fellows:
Italy Eligibility of fellows:
country/ies of residence:
OTHER Eligibility of fellows:
nationality/ies:
OTHER Web site for additional